Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit
Filed with ASX · · 2 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallNew York, USA; December 29 and Melbourne, Australia; December 30, 2025: Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has repaid in full its existing senior secured loan from Oaktree Capital Management, Inc. and in part its subordinated royalty facility from NovaQuest Capital Management LLC by drawing dow
Story so far
Earlier from Mesoblast
- Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
- Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
- Mesoblast Participation at Piper Sandler Conference
- Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
- Ryoncil Revenue Growth Highlighted in AGM Trading Update
Later from Mesoblast
- Mesoblast Announces Changes to Board of Directors' Leadership Roles
- Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
- Ryoncil Sales for the Quarter Increase 60% to US$35.1M
- FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
- Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast